Skip to main content
European Radiology Experimental
Fig. 2 | European Radiology Experimental

Fig. 2

From: Hyperpolarized [1-13C]-pyruvate MRS evaluates immune potential and predicts response to radiotherapy in cervical cancer

Fig. 2

Hyperpolarized MR study protocol. The doses were prepared in a sterile environment and polarized on the same day as the patient’s visit. After the magnetic resonance scanning field was calibrated and localized, the hyperpolarized (HP) [1-13C]-pyruvate was dissolved and transferred into the scanner via a window (blue box) and administered to the patient intravenously. Dynamic 13C magnetic resonance spectroscopy (MRS) was performed 30 s after injection to track the delivery and metabolism of HP [1-13C]-pyruvate in the spleen. This was followed by dynamic 13C magnetic resonance imaging (MRI) and a single-timepoint 13C spectroscopic imaging (MRSI) to confirm the origin of HP 13C signals

Back to article page